newsfilter
← Latest News
GlobeNewswire·

Bolt Biotherapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update

Next-generation claudin 18.2 ISAC BDC-4182 now in Phase 1 dose-escalation study Cash balance of $48.5 million as of June 30, 2025 anticipated to fund key milestones through mid-2026 REDWOOD CITY, Calif., Aug. 14,